VRTX (STOCKS)
Vertex Pharmaceuticals Inc
$450.460000
+5.535000 (+1.24%)
Prev close: $444.925000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Reshma Kewalramani
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $114,329.19M
- Employees
- 6,100
- P/E (TTM)
- 26.38
- P/B (TTM)
- 5.84
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
13
Strong Buy
20
Buy
6
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$4.47 | $4.40 | +0.0736 | +1.67% |
|
Dec 2025 (Q4)
|
$5.03 | $5.17 | -0.1444 | -2.79% |
|
Sep 2025 (Q3)
|
$4.80 | $4.65 | +0.1453 | +3.12% |
|
Jun 2025 (Q2)
|
$4.52 | $4.37 | +0.1507 | +3.45% |
Financial Statements
| Revenues | $12.22B |
| Benefits Costs and Expenses | $7.05B |
| Cost Of Revenue | $1.68B |
| Costs And Expenses | $7.54B |
| Gross Profit | $10.54B |
| Operating Expenses | $5.86B |
| Selling, General, and Administrative Expenses | $1.85B |
| Other Operating Expenses | $4.01B |
| Operating Income/Loss | $4.68B |
| Income/Loss From Continuing Operations After Tax | $4.34B |
| Income/Loss From Continuing Operations Before Tax | $5.17B |
| Income Tax Expense/Benefit | $827.40M |
| Net Income/Loss | $4.34B |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $4.34B |
| Net Income/Loss Available To Common Stockholders, Basic | $4.34B |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $17.01 |
| Diluted Earnings Per Share | $16.85 |
| Basic Average Shares | 765,700,000 |
| Diluted Average Shares | 772,200,000 |
| Assets | $26.48B |
| Current Assets | $11.73B |
| Inventory | $1.77B |
| Other Current Assets | $9.96B |
| Noncurrent Assets | $14.75B |
| Intangible Assets | $418.50M |
| Other Non-current Assets | $14.34B |
| Liabilities | $7.12B |
| Current Liabilities | $3.88B |
| Accounts Payable | $489.30M |
| Other Current Liabilities | $3.39B |
| Noncurrent Liabilities | $3.24B |
| Equity | $19.36B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $19.36B |
| Liabilities And Equity | $26.48B |
| Net Cash Flow From Operating Activities | $4.24B |
| Net Cash Flow From Operating Activities, Continuing | $4.24B |
| Net Cash Flow From Investing Activities | -$1.32B |
| Net Cash Flow From Investing Activities, Continuing | -$1.32B |
| Net Cash Flow From Financing Activities | -$2.12B |
| Net Cash Flow From Financing Activities, Continuing | -$2.12B |
| Exchange Gains/Losses | $20.10M |
| Net Cash Flow | $819.50M |
| Net Cash Flow, Continuing | $799.40M |
| Comprehensive Income/Loss | $4.30B |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $4.30B |
| Other Comprehensive Income/Loss | $4.30B |
| Other Comprehensive Income/Loss Attributable To Parent | -$43.30M |